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Abstract
Familial hypercholesterolemia (FH) is caused by a major genetic defect in the low-density
lipoprotein (LDL) clearance pathway. Characterised by LDL-cholesterol elevation from birth,
FH confers a significant risk for premature coronary artery disease (CAD) if overlooked and
untreated. With risk exposure beginning at birth, early detection and intervention is crucial
for the prevention of CAD. Lowering LDL-cholesterol with lifestyle and statin therapy can
reduce the risk of CAD. However, most individuals with FH will not reach guideline
recommended LDL-cholesterol targets. FH has an estimated prevalence of approximately
1:250 in the community. Multiple strategies are required for screening, diagnosing and
treating FH. Recent publications on FH provide new data for developing models of care,
including new therapies. This review provides an overview of FH and outlines some recent
advances in the care of FH for the prevention of CAD in affected families. The future care of
FH in Australia should be developed within the context of the National Health Genomics
Policy Framework.
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Introduction
Familial hypercholesterolemia (FH), characterised by high plasma low-density lipoprotein
(LDL)-cholesterol levels and a strong risk of premature coronary artery disease (CAD), is the
most common autosomal dominantly inherited genetic disorder (Figure 1) [1, 2]. FH is
classified by the Centers for Disease Control and Prevention as a tier 1 genomic application
[3]. A tier 1 genomic application is consider as a preventable cause of premature disease
and death, with significant potential for positive impact on public health based on available
evidence-based guidelines and recommendations [3]. FH is more common than other tier 1
genomic applications, such as hereditary breast and ovarian cancer syndrome and Lynch
syndrome [4].
Since FH is an inherited condition with risk exposure beginning at birth, early detection and
intervention is crucial for the prevention of CAD. With an estimated prevalence of
approximately 1:250 [5] in the general population, FH represents a major gap in
preventative medicine and is clearly a public health problem. Reflecting the public health
challenges that FH poses, gaps in care are currently being addressed by clinicians and
researchers around the world [6, 7].
The purpose of this review is to provide a contemporary overview of core information and
advances that may be employed to improve healthcare and therapy to prevent premature
CAD in patients and families with FH.
Molecular pathophysiology
LDL-cholesterol is cleared from circulation via LDL-receptors (LDLR) in the liver. In FH, there
is a disturbance to this clearance pathway and subsequently, an increase in the plasma
concentration of LDL-cholesterol [8]. Genetic defects that impair the LDLR pathway include
variants in the LDLR gene itself, variants in the APOB (apolipoprotein B, the receptor ligand)
gene and/or variants in the PCSK9 (proprotein convertase subtilisin/kexin type 9; an enzyme
that regulates cell surface receptors that degrades LDLR) gene. The inheritance of FH is
autosomal dominant; individuals with heterozygous FH (heFH) have 50% chance of
transmitting the mutation to each offspring. If both parents have heFH, there is a chance of
an offspring inheriting two FH variants, resulting in homozygous, compound or double
heterozygous FH (hoFH) [9].
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In FH, plasma LDL-cholesterol concentrations are markedly elevated from birth and if
untreated can lead to an acceleration of foam cell formation and atherosclerotic plaques in
the arterial wall, principally in proximal coronary arteries and the aorta. Atherogenesis is
proportional to the LDL-cholesterol burden over time and hence, development of
atherosclerosis is much more severe in hoFH than in heFH. If undiagnosed and untreated,
the risk of CAD in heFH is more than 50% by the age of 50 in men and at least 30% by the
age of 60 in women [10]. HoFH patients tend to exhibit an aggressive coronary
atherosclerosis before the age of 20 [9].
Prevalence
The theoretical prevalence of heFH was commonly considered to be 1:500 [11], more
extensive and contemporary studies, some based on genetic testing, have now suggested
that the prevalence of heFH in the community is approximately 1:250 [12-14]. The
prevalence of hoFH is considered to be between 1:160,000 and 1:300,000 [9, 15], and
higher in some populations owing to a founder-effect [16], such as in the Afrikaners (1:70)
and Lithuanian Jewish (1:70) populations [10]. Knowledge of the prevalence of FH allows the
extent of under-diagnosis to be estimated, and perhaps with the exception of the
Netherlands and Norway, FH is globally under-diagnosed [17, 18].
The prevalence of heFH in younger hypercholesterolaemic patients with premature CAD can
be as high as 1:10 [19]. Therefore, major efforts should be made to screen for FH in these
patients and to initiate cascade testing of close family members for primary as well as
secondary prevention.
Screening and Detection
Cases of FH may be detected using selective (eg. selective screening of high-risk coronary
patient), systematic (eg. systematic screening of family members from a known index case),
opportunistic (eg. opportunistic alerts on pathology reports and in primary care) and
universal (eg. screening of all newborns or children at immunisation) screening strategies.
However, the feasibility and cost-effectiveness of implementing and integrating these
approaches remains to be demonstrated [20, 21], and are highly dependent on the existing
health system.
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Selective screening of patients with premature CAD offers a high yield but does not allow for
the primary prevention of CAD in the index case. This is important, given that the first
clinical presentation of CAD can actually be sudden death [22]. Selective screening of school
children is another option but a recent study demonstrated a low rate of uptake [23].
Screening employing genetic testing in biobanks [24] and blood donors [25] are recent
opportunistic approaches. Cascade screening remains the classical systematic method for
detecting new cases but relies a priori on identifying an index case. A proposed method of
cascade screening is depicted in Figure 2. A centralised service approach for cascade
screening has been demonstrated to be cost-effective in Australia and the UK [26, 27].
Population modelling has suggested that to detect the majority of FH cases in the
community requires more than just cascade testing [28]. Hence, universal screening now
needs serious consideration, especially in children [29]. Universal screening of children
combined with child-parent “reverse” cascade testing is potentially the most effective
method for detecting most cases of FH in the community and prior to the development of
CAD [30]; this approach appears to be acceptable [31] and cost-effective [32]. However, this
strategy has only been implemented in Slovenia [33] (which has a population of
approximately 2 million) and requires adaptation and evaluation in countries with different
healthcare systems, larger populations and geographical areas, as well as addressing
concerns related to logistics and anxiety amongst parents.
From a community perspective, there is great potential for primary care physicians to play a
much greater role in the detection and management of FH [34]. In Australia, over 87% of the
population consult a general practitioner (GP) at least once a year [35] and over 90% of LDLcholesterol tests undertaken through a community-based pathology laboratory are
requested by GPs [36]. It is increasingly recognised that this ease of access could be
harnessed to encourage greater awareness and use of opportunistic screening for the
condition as part of regular surgery consultations, with a potential for cascade testing of
relatives within the same practice. Additionally, community screening in general practice
can be supported by digital technology for searching electronic health records for potential
cases of FH [37-40].
Clinical Diagnosis
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An elevated untreated LDL-cholesterol is the major phenotypic criterion for diagnosing FH.
However, a wide overlap exists in plasma LDL-cholesterol levels between patients with and
without heFH or hoFH [41] (Figure 3). The Dutch Lipid Clinic Network Score (DLCNS) (Figure
4) is the most widely used phenotypic method for diagnosing adult index cases with heFH
[6] and is based on several key criteria including the patient’s family history of premature
CAD, personal history of premature CAD, their untreated LDL-cholesterol level and physical
stigmata such as tendon xanthomata and/or arcus cornealis. Recent US guidelines have
defined FH in adults using simply a family history of premature CAD and an elevated plasma
LDL-cholesterol level >4.9 mmol/L [21, 42]. However, concordance with the genetic
diagnosis of FH can be low [43]. As familial elevation of lipoprotein(a) [Lp(a); an LDL-like
particle] can be a common phenotypic mimic of FH, adjustments for the cholesterol content
of Lp(a) in LDL-cholesterol could improve diagnosis in some cases [44], but this is not widely
appreciated nor practiced. Paediatric index cases of FH may be diagnosed phenotypically as
an LDL-cholesterol of >5 mmol/L (on two separate occasions) or as an LDL-cholesterol >4
mmol/L with high cholesterol in one parent [2].
LDL-cholesterol alone is also the major phenotypic criterion for diagnosing FH in first-degree
family members of an index case. The detection of FH in first-degree relatives should not be
made using DLCNS, which was designed for making the diagnosis of FH in index cases. There
is obviously a much higher probability of first-degree relatives of a definite FH proband
having FH (50% vs. 1 in 250 in the community). LDL-cholesterol thresholds, with adjustments
for age and gender, for use in cascade testing of relatives of index cases are shown in
(Figure 5) [45].
Given the ambiguities in making a contemporary diagnosis of heFH and hoFH, a phenotypic
definition of “severe FH” was proposed by an international consensus panel. Severe FH was
defined as a plasma LDL-cholesterol level >10.0 mmol/L alone, >8.0 mmol/L plus one high
cardiovascular risk, or >5.0 mmol/L plus two high cardiovascular risk [46]. This definition has
recently been shown to predict an adverse cardiovascular outcome [47]. Although the
definition is pragmatic and has clinical appeal, the definition undermines the merits of
precision offered by genetic testing.
Genetic Testing
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Cost-effective deployment of lipid-lowering therapies and the decision to cascade test
family members is reliant on an accurate diagnosis of heFH. The use of genetic testing
allows an accurate diagnosis of heFH and hoFH and is also important for risk stratification
[12]. The extent of cholesterol elevation and atherogenesis in FH is dependent on the
severity of the genetic variant [48], whether the variant affects receptor synthesis,
transport, binding, internalisation and/or recycling. Genetic testing has a role in preconception genetic counselling and a special role in the care of hoFH [41], in the prediction
of responsiveness to certain therapies for those with null mutations (no LDLR activity) [49].
Although the detection of a pathogenic variant for FH is the gold standard for diagnosis [41],
genetic testing also has several barriers, such as cost implications, issues with variant
interpretation [50], restrictions on life insurance and under-availability of genetic
counselling services [51]. Genetic testing is not at present widely available, although this
could change rapidly in the new era of widespread next-generation sequencing (massively
parallel sequencing) [52]. Frameworks for genetic counselling of families with FH are
fundamental to clinical practice and has been emphasised in recent guidelines [41].
Genetic testing for FH has been proposed by the Medical Services Advisory Committee as an
item that should be listed on the Medicare Benefits Schedule (MBS). As with other genetic
conditions, all testing and reporting in Australia must comply with the requirements of the
National Pathology Accreditation Advisory Council [53]. A National Health Genomics Policy
Framework has also been developed to co-ordinate a strategic approach to incorporate
genomics into the health system [54]. This has the general aim of employing genomics to
improve health outcomes and quality of life for the Australian population and this has
implications for people with FH. Success of implementation will be underpinned by effective
digital health technology [55]. The strategic priority areas and their relevance to FH are
highlighted in Table 1.
Risk Assessment
There is wide variation in the risk of CAD among FH. Severity of FH is proportional to
severity of the mutation and the total burden of LDL-cholesterol (heFH and hoFH). At even
?every level of LDL-cholesterol, presence of a mutation predicts risk [12].
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Traditional risk factors are well recognised to increase cardiovascular disease (CVD) risk in
FH [56]. Estimating risk is important to guide therapy, particularly in those at the presymptomatic stage. Risk prediction algorithms employing CVD risk factors have been
developed specifically in genetically defined FH cohorts in Canada and Spain [57, 58].
However, these models require further validation in other sample populations.
Genetic risk factors, such as an elevation in plasma Lp(a) concentration [59, 60], a high
genetic CAD risk score or high polygenic cholesterol score [61-63], can predict adverse CVD
risk, particularly in genetically defined FH. Variants in the 9p21.3 loci and ABO blood group
have also been associated with higher risk of CVD in FH [62, 64]. Of these genetic risk
factors, recent data demonstrates value in assessing Lp(a) concentration in FH and during
cascade testing of family members [65, 66]. However, the extent to which the genetic risk
scores extend to different ethnic groups remains to be determined [67, 68]; their clinical use
also requires further evaluation.
Imaging of pre-clinical atherosclerosis may currently be the most valuable tool for assessing
risk in FH. Coronary artery calcium (CAC) measurements can be done quickly and cheaply.
CAC scores are independently associated with subsequent coronary events in patients with
FH receiving standard lipid-lowering therapy [69]. Compared with CAC, coronary computed
tomography angiography (CCTA) takes more time, involves radiation exposure and requires
a controlled heart rates with a venous injection of contrast. However, it can more accurately
assess the burden of both soft and calcified plaque burden. CCTA has been demonstrated to
identify the very early development of coronary atherosclerosis in heFH subjects and the
magnitude of coronary plaque burden can predict future coronary events [70]. CCTA and
CAC can be undertaken together for more accurate delineation of disease burden and
prospective risk stratification of asymptomatic heFH subjects [71]. However, the precise
economic and patient-level impact of coronary imaging remains to be demonstrated. Recent
European guidelines have recommended that asymptomatic individuals with a strong family
history of premature CAD, such as FH, be considered for CCTA [72]. Additionally, it has been
recommended that unequivocal evidence of CVD on imaging in FH should be considered at
very-high cardiovascular risk [73].
Carotid-intima media thickness (CIMT) on ultrasonography may be useful to detect early
atherosclerosis in FH [2, 74]. CIMT has been shown to be responsive to LDL-cholesterol
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reduction with statin therapy and has recently been shown to be associated with reductions
in cardiovascular outcomes in children over 20 years [75, 76]. Measurement of carotid
plaque burden with 3D ultrasound may be more valid than CIMT for estimating
atherosclerosis burden in adult patients, but its role in clinical management remains to be
established [77-79].
Management
Treatment of elevated LDL-cholesterol in FH involves dietary, lifestyle management and
pharmacotherapy. Statins are the mainstay pharmacotherapy and is supported by new
evidence from cohort and registry data [80-82], long-term follow-up data from relevant
clinical-endpoint trials [83] and surrogate-endpoint studies [75, 84]. However, a significant
proportion of patients do not reach LDL-cholesterol targets on high-intensity statins [85, 86]
and additional therapy with ezetimibe and/or bile-acid sequestrants may be required [8790]. Supported by clinical trial data in non-FH populations, PCSK9 inhibitors are
recommended as third-line therapy to treat FH [42, 73, 91-97] (Figure 6). Drug interactions
and toxicity needs to be monitored in FH given that the majority of adult patients will be on
two or more drugs, with appropriate investigations of renal, liver and glucose biochemistry
[20, 21].
Adults
The recommended initial treatment target for FH has been a 50% reduction in plasma LDLcholesterol concentration [42], followed by an LDL-cholesterol <2.6 mmol/L (no CVD or
major risk factors) and <1.8 mmol/L (CVD or major risk factors)[20, 98, 99]. However, recent
guidelines from the American Association of Clinical Endocrinologists (AACE) and the
European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) have
recommended an LDL-cholesterol of <1.8 mmol/L for primary prevention and <1.4 mmol/L
for secondary prevention (or very-high risk) [73, 100]. Recent data suggest that the use of
these treatment targets are probably unrealistic for FH patients [101].
The two PCSK9 inhibitors registered in Australia are Repatha (evolocumab) and Praluent
(alirocumab). The Pharmaceutical Benefits Scheme (PBS) allows a PCSK9 inhibitor be offered
to hoFH and heFH patients meeting the sets of eligibility criteria detailed in Table 2.
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Dietary (eg. heart healthy diet) and lifestyle (eg. exercise and avoidance of smoking)
management is adjunctive to pharmacotherapy and may be the only treatment option for
certain groups, such as pregnant women, younger children and individuals with a
pathogenic FH-causing mutation that has yet to express as hypercholesterolemia [12, 102].
Although statins are contra-indicated in pregnancy and during breastfeeding [103, 104], no
association has been reported in cohort studies for birth defects, preterm delivery or lower
birth weights [105, 106]. In a recent study, the use of statins in hoFH women during
pregnancy was reported to be safe for both mother and foetus [107], particularly when
taken in the second and third trimester. PCSK9 inhibitors cross the placenta and should not
be used in pregnancy [99]. PCSK9 inhibitors and are also not licenced for use in children.
Children
Mendelian randomisation [108, 109] and observational studies [76] provide evidence that
FH patients should receive aggressive, life-long lifestyle management and initiate lipidlowering therapy from an early age. A recent study from the Netherlands comparing
cumulative incidence of cardiovascular events in FH patients who commenced statin
therapy during childhood (8-18 years) to their affected parents who commenced on statin
therapy later in life (20-51 years) was 1% vs 26% (Figure 7). Expert recommendations are
that statins should be initiated in children with heFH between the ages of 5 and 10 years [2,
42, 73, 110], or earlier according to shared decision making with parents [2, 21, 99]; children
with hoFH should be treated with statins and additional therapies at diagnosis. Guideline
recommended targets are a 50% reduction in plasma LDL-cholesterol concentration [110] or
LDL-cholesterol <3.5 mmol/l for heFH [2], and <2.6 mmol/L [111] and <1.8 mmol/L for hoFH
children without and with symptomatic ASCVD, respectively [9, 111]. However, these
targets may not be achievable in clinical practice with contemporary treatments approved
for use in children.
Apheresis
All contemporary guidelines recommend lipoprotein apheresis (LA) for hoFH and severe
heFH patients, who remain above LDL-cholesterol treatment targets despite being on
maximal drug therapy [20, 46, 112, 113]. Recent studies confirm that the cardiovascular
benefits of LA are related to the degree of reduction in the cumulative exposure to LDLPage 10 of 34

cholesterol [114-116], but pleiotropic effects may play a role, particularly reduction in
arterial inflammation [117]. However, apheresis is not widely available or practiced [112].
PCSK9 inhibitors reduce the need for LA in heFH [118] and can further lower LDL-cholesterol
in hoFH patients on LA [119]. As a final option, liver transplantation may be an effective
therapy for younger patients with hoFH and rapidly progressive atherosclerosis [120, 121].
New therapies
Several new therapies for lowering LDL-cholesterol are in development or in the early
phases of clinical trials [95, 122, 123]. These agents could have indications for FH patients
who cannot tolerate maximal doses of currently available pharmacotherapies or who have
refractory hoFH. Beyond monoclonal antibodies, PCSK9 may be targeted with small
interfering RNA (Inclisiran) [124], which is undergoing testing in cardiovascular outcomes
trials, and with gene-editing approaches, which are at an early experimental stage [122,
123]. For hoFH patients, therapies that act independent of the LDL receptor pathway, such
as a inhibitors of ANGPTL3 (evinacumab) [125] offer new opportunities for further lowering
of LDL-cholesterol [122].
Adherence
Poor adherence to treatment is associated with increased risk of CVD [126, 127]. Hence, it is
vital to carefully address patient concerns and beliefs about medication [128], as well as the
impact of media reports on the adverse perceptions of statins [129, 130]. In an era of
personalised and participatory medicine [42], the care of FH must be patient-centred to
improve the quality of decision making process [131, 132], and this may be facilitated by the
use of decision aids [133]. As with other chronic disorders, health literacy issues in FH must
be addressed to ensure adherence to therapies [134].
Organisation of Care
The optimal care of FH requires a systems approach to the provision of services [1].
Organisational aspects of FH healthcare need to be designed according to available
resources and contexts and be integrated across a continuum to deliver a life-long
management plan. A multi-disciplinary approach is fundamental; key disciplines include
general practice [135], cardiology, paediatrics, genetics, imaging and transfusion medicine,
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with support from allied health professionals experienced in nursing, dietetics, psychology
and pharmacy [136]. Design and implementation of models of care also should involve
government policy makers, patients and families, as well as patient advocates and the wider
public [137, 138].
From a community perspective, it has been recommended that most individuals diagnosed
with FH should be treated in primary care and preferably in a family context, with more
complex cases including children referred to specialised lipid or FH clinics [98]. The potential
to optimise a “shared care” model between primary care and specialist services is attractive
and is well recognised [98, 139]. The UK has established specialist regional lipid clinics to
support GPs and practices which has resulted in greater detection of FH in the community
[140].
Patient support groups and networks are essential for advocating improvement in care and
are a vital component of modern-day participatory medicine, being also well aligned with a
central theme of the National Health Genomics Policy Framework [54]. Beyond providing
awareness raising through social media [141], general education and counselling,
international achievements to date are evidenced by government run screening programs,
inception and growth of national registries, support for new screening strategies and
improvements in access to effective therapies [142]. The last is particularly relevant at a
time of access barriers to new therapies [143]. The value of patient support networks are
classically exemplified by the activities of the US FH Foundation and the European FH
Patient Network [142].
Clinical Registries
The primary function of quality clinical registries is the collection of data on patients in a
systemic and standardised way that reflects “real world” clinical practice. Clinical registries
on FH meet a key requirement of the 1998 World Health Organisation Report [144] and
have now been promulgated in several countries [145, 146]. Registries are important not
only to raise overall awareness of FH, but also to collect information for clinical trials and for
healthcare policy and planning as a means for improving the quality of patient care and
outcomes [147]. In Australia, a web-based registry for FH has been established since 2015
with over 40 clinical sites nationally [148] (Figure 8); preliminary analysis of the extant data
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confirms that in Australia the shortfalls in the detection and care of FH reflect that of other
countries [6].
In order to capture a large global FH dataset, the Familial Hypercholesterolemia Studies
Collaboration (FHSC) initiative aims to collect data from FH investigators worldwide [7, 145].
To improve the precision of data acquisition and analyses, a more specific ICD-10 code for
FH has been introduced in the US [21], but requires consistent application at an
international level [149].
Research
A scientific statement from the American Heart Association has identified a number of key
research needs in FH [21]. An agenda has been proposed that serves as a useful template
for developing context-specific research programs. The main themes are basic science, life
course, clinical research, patient-centric research, models of care and population science
[20]. Healthcare gaps need to be closed through adequately funded research that addresses
these themes [20, 21]. The value of implementation research in effectively translating
evidence into practice has been more recently emphasised [4, 150].
Educational and Training Needs
The National Health Genomics Policy Framework emphasises a core need to upskill health
care professionals in genomics [54], and this clearly extends to FH noting the potentially
imminent incorporation of genetic testing into the clinical care of FH in Australia [151].
Several surveys have shown that healthcare professionals, including primary care physicians
and cardiologists, lack awareness, knowledge and skills relating to the epidemiological,
genetic, clinical and therapeutic aspects of FH [152-156]. Strategies are required to ensure
the inclusion of adequate skills within professional development programs. General
practitioners, cardiologists, pharmacists and nurses are ideally placed to identify and
manage individuals with FH. Education and training of these healthcare professionals is
important for improving and maintaining quality care [20]. Physicians and nurses managing
patients with FH should ideally have certified training in clinical lipidology and competencies
in preventative cardiology and clinical genetics [1, 157].
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From a primary care perspective, beyond gaps in fundamental knowledge of FH, there is a
major need to train and upskill staff in basic genetic counselling methods [158] and the
effective implementation of cascade testing of first- and second-degree relatives of index
cases. The effective integration of primary care within comprehensive screening strategies
for FH is dependent on increasing the capabilities, opportunities and motivation of GPs.
Conclusions
As a leading tier 1 genomic application [3], FH has great potential to prevent premature
disease and death. The key major advances in FH have been in genetics, imaging, registries
and therapies. Despite exponential advances in knowledge, there is a significant shortfall in
the detection and treatment of this relatively common inherited cause of premature CAD.
This relates to a shortfall in patient, provider, organisational, policy and community
awareness factors. A major challenge is translating new evidence into health policy and high
quality care and implementation research is a core function [137] for improving outcomes
of FH patients over their life-span. Updating the World Health Organisation Report from 20
years ago is a critical first step for effectively implementing improved care of FH [159],
which is now a global health priority [160]. Developments in genomics and digital health
now need to be embedded into the evolving model of care of FH in Australia and beyond.
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Figure 1. The prevalence of familial hypercholesterolaemia is more common than other
genetic diseases, adapted from Wiegman et al 2015 [2]. FH is a leading tier 1 genomic
application [3].
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Figure 2. This is a scheme for approaching and risk notification of family members during
cascade testing of families for FH. Adapted from Bell et al 2015 [161] and Kullo et al 2018
[162].
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Figure 3. The phenotypic and genetic spectrum of familial hypercholesterolemia and the
estimated risk of coronary artery disease, adapted from Sturm et al 2018 [41].
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Figure 4. The Dutch Lipid Clinic Network criteria for making a diagnosis of familial
hypercholesterolaemia in adult index cases, adapted from the World Health Organisation
[144].
Criteria*

Score

Section 1: Family history
First degree relative with known premature coronary and/or vascular disease (men aged <55 years,
women aged <60 years)
OR
th
First degree relative with known LDL-cholesterol above the 95 percentile for age and gender

1

First degree relative with tendinous xanthomata and/or arcus cornealis
OR
th
Children aged <18 years with LDL-cholesterol above the 95 percentile for age and gender

2

Section 2: Clinical history
Patients with premature coronary artery disease (men aged <55 years, women aged <60 years)

2

Patients with premature cerebral or peripheral vascular disease (men aged <55 years, women aged
<60 years)

1

Section 3: Physical examination
Tendinous xanthomata

6

Arcus cornealis before 45 years of age

4

Section 3: Biochemical results
LDL-cholesterol (mmol/L)

LDL-cholesterol ≥8.5

8

LDL-cholesterol 6.5–8.4

5

LDL-cholesterol 5.0–6.4

3

LDL-cholesterol 4.0–4.9

1

*Note that only the highest score in each section is chosen to add up to the total score, to a maximum of 18.

Diagnosis

Total
Score

Definite FH

>8

Probable FH

6-8

Possible FH

3-5

Unlikely FH

<3
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Figure 5. LDL-cholesterol cut-offs for the diagnosis of FH in cascade testing, based on age
and gender, in first-degree relatives of FH patients: (A) for females and (B) for males.
Adapted from Starr et al 2008 [45].

Colour
Red
Grey
Green

Likelihood of FH
Likely
Uncertain
Unlikely
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Figure 6. Simplified treatment scheme for adults with familial hypercholesterolemia.
Shared-decisions should be practice at each step of treatment. Adapted from Gidding et al
2015 [21].

High-intensity statin therapy

If LDL-cholesterol is above guideline recommended threshold*

High-intensity statin +
Ezetimibe

If LDL-cholesterol is above guideline recommended threshold*

High-intensity statin +
Ezetimibe + PCSK9 inhibitor

If LDL-cholesterol is above guideline recommended threshold*

High-intensity statin +
Ezetimibe + PCSK9 inhibitor +
LDL apheresis

*Guideline recommended threshold based on primary or secondary prevention; patient
should be on at least 3 months of therapy, is adherent and treatment is tolerable.
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Figure 7. Kaplan-Meier curves of cardiovascular event-free survival in patients with familial
hypercholesterolaenmia who commenced statin therapy during childhood (8-18 years) and
their affected parents who commenced on statin therapy later in life (20-51 years) [76].
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Figure 8. Clinical sites of the Australian FH registry, which includes the public and private
sector. Data from all sites are entered onto a secure web-based registry platform [148].

6
8

8

5

2
12

2

Page 23 of 34

Table 1. Five key priorities of the National Health Genomics Policy Framework [54] and
examples of their application to the diagnosis and management of familial
hypercholesterolaemia. Successful implementation of the framework is underpinned by
digital innovation and technology [55].

Strategic priority areas
Person-centred
approach

Workforce

Financing

Services

Data

Provide support
for FH individuals
and their families
to make
informed choices
in genetic
testing; support
patient advocacy
groups and the
public to
promote
awareness for FH

Build capacity for
improving skills
and literacy of
health care
professionals in
genomics,
employing
evidence-based
education and
training
programs for
managing FH

Ensure
sustainable and
strategic
investment in
cost-effective use
of genetic testing
in the diagnosis
and management
of FH patients;
support for
evidenced-based
models of care

Promote
evidence-based
and nationally
consistent best
practice in
genetic testing
and counselling
services for FH
and their
incorporation
into models of
care integrated
across primary
and specialist
care

Develop a high
quality national
register to enable
screening, data
collection,
storage, sharing,
analysis and
reporting
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Table 2. Pharmaceutical Benefits Scheme eligibility criteria for Repatha (evolocumab) for
homozygous and heterozygous familial hypercholesterolaemia in Australia. Praluent
(alirocumab) has been recommend for heterozygous familial hypercholesterolaemia.

Criteria
Diagnosis
LDL cholesterol

HoFH
DLCNS ≥7 OR
Confirmed by genetic testing
>3.3 mmol/L

HeFH
DLCNS ≥6 OR
Confirmed by genetic testing
>5 mmol/L OR
>3.3 mmol/L plus symptomatic
atherosclerotic cardiovascular disease

Maximum recommended dose of Atorvastatin
or Rosuvastatin for ≥3 months OR
Statin contraindicated as defined by the
TGA-approved Product Information

Treatment

OR
Clinically important productrelated adverse event
necessitating a withdrawal of
statin treatment

OR
Clinically important product-related
adverse event necessitating withdrawal
of statin treatment to trials of each
Atorvastatin and Rosuvastatin
AND
In conjunction with dietary therapy and exercise for ≥3 months
AND
On ezetimibe ≥3 months
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